WHWKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Whitehawk Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.01+0.12 (+4.15%)
Close on Oct 19, 2026
- Market cap
- $249.49M
- P/E (TTM)
- –
- Dividend yield
- –
Whitehawk Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Whitehawk Therapeutics | Industry median |
|---|---|---|
| Market Cap | $171.60M | $166.30M |
| Enterprise Value | -$18.40M | $87.12M |
| PB Ratio | 0.94 | 2.03 |
| P/TBV Ratio | 0.94 | 2.31 |
Income (trailing twelve months)
| Measure | Whitehawk Therapeutics | Industry median |
|---|---|---|
| Revenue | $0 | $57.94M |
| Gross Profit | $0 | $90.47M |
| Operating Income | -$86.06M | -$21.49M |
| Net Income | -$79.83M | -$22.46M |
| EBITDA | -$86.06M | -$17.14M |
Returns
| Measure | Whitehawk Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -45.0% | -53.2% |
| Return on Assets (ROA) | -42.6% | -41.0% |
| Return on Capital Employed (ROCE) | -47.0% | -38.0% |
Growth
| Measure | Whitehawk Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -100.0% | 6.01% |
| Revenue Growth (3Y CAGR) | -22.3% | 2.25% |
| Revenue Growth (5Y CAGR) | -12.6% | 6.42% |
Balance sheet
| Measure | Whitehawk Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $190.00M | $62.64M |
| Net Cash (Debt) | $190.00M | $15.77M |
| Net Cash Per Share | $3.33 | $0.66 |
| Equity (Book Value) | $182.93M | $48.61M |
| Book Value Per Share | $3.21 | $1.36 |
| Tangible Book Value | $182.93M | $23.01M |
| Working Capital | $181.35M | $75.09M |
Financial position
| Measure | Whitehawk Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 17.38 | 3.30 |
| Quick Ratio | 17.17 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Whitehawk Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$69.35M | -$12.39M |
| Capital Expenditures | $0 | -$1.07M |
| Free Cash Flow | -$69.35M | -$20.34M |
| FCF Per Share | -$1.22 | -$0.42 |
Efficiency
| Measure | Whitehawk Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.38 |
| Revenue Per Employee | $0 | $398.96K |
| Profits Per Employee | -$3.47M | -$705.27K |
| Employee Count | 23 | 74 |
Dividends and yields
| Measure | Whitehawk Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -46.5% | -22.8% |
| FCF Yield | -40.4% | -9.02% |
Shares
| Measure | Whitehawk Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 57,009,000 | 58,139,000 |
| Shares Change (YoY) | 77.0% | 11.1% |
| Shares Change (QoQ) | 20.8% | 0.54% |
| Float | 28,559,600 | 49,154,900 |
| Shares Held by Insiders | 49.9% | 11.6% |
| Shares Held by Institutions | 75.8% | 59.4% |
Taxes
| Measure | Whitehawk Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $89.00K |
Scores
| Measure | Whitehawk Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 6.13 | -0.27 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -2.17 | -2.62 |
Calculated by StockData from Whitehawk Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.